33 results on '"Buchholz, Tonia J."'
Search Results
2. Data from Antitumor Activity of PR-171, a Novel Irreversible Inhibitor of the Proteasome
3. Supplementary Figure 2 from Antitumor Activity of PR-171, a Novel Irreversible Inhibitor of the Proteasome
4. Supplementary Figure 1 from Antitumor Activity of PR-171, a Novel Irreversible Inhibitor of the Proteasome
5. Data from Antitumor Activity of PR-171, a Novel Irreversible Inhibitor of the Proteasome
6. Supplementary Figure 1 from Antitumor Activity of PR-171, a Novel Irreversible Inhibitor of the Proteasome
7. Clinical Activity of BMS-986393 (CC-95266), a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients with Relapsed and/or Refractory (R/R) Multiple Myeloma (MM): First Results from a Phase 1, Multicenter, Open-Label Study
8. Poster: ABCL-412 Clinical Activity of CC-99282, a Novel, Oral, Small Molecule Cereblon E3 Ligase Modulator (CELMoD) Agent, in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma (R/R NHL) –Results From CC-99282-NHL-001 (NCT03930953) a First-in-Human, Phase 1, Open-Label, Multicenter Study
9. ABCL-412 Clinical Activity of CC-99282, a Novel, Oral, Small Molecule Cereblon E3 Ligase Modulator (CELMoD) Agent, in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma (R/R NHL) –Results From CC-99282-NHL-001 (NCT03930953) a First-in-Human, Phase 1, Open-Label, Multicenter Study
10. Clinical Activity of CC-99282, a Novel, Oral Small Molecule Cereblon E3 Ligase Modulator (CELMoD) Agent, in Patients (Pts) with Relapsed or Refractory Non-Hodgkin Lymphoma (R/R NHL) - First Results from a Phase 1, Open-Label Study
11. Modular Polyketide Synthases
12. Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier
13. Pharmacodynamic Responses to CC-90009, a Novel Cereblon E3 Ligase Modulator, in a Phase I Dose-Escalation Study in Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)
14. Clinical Activity of CC-90009, a Cereblon E3 Ligase Modulator and First-in-Class GSPT1 Degrader, As a Single Agent in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML): First Results from a Phase I Dose-Finding Study
15. Immunoproteasome functions explained by divergence in cleavage specificity and regulation
16. Author response: Immunoproteasome functions explained by divergence in cleavage specificity and regulation
17. The immunoproteasome β5i subunit is a key contributor to ictogenesis in a rat model of chronic epilepsy
18. Paradoxical resistance of multiple myeloma to proteasome inhibitors by decreased levels of 19S proteasomal subunits
19. Author response: Paradoxical resistance of multiple myeloma to proteasome inhibitors by decreased levels of 19S proteasomal subunits
20. Development of a Capillary Electrophoresis Platform for Identifying Inhibitors of Protein–Protein Interactions
21. Biochemical and Structural Characterization of Germicidin Synthase: Analysis of a Type III Polyketide Synthase That Employs Acyl-ACP as a Starter Unit Donor
22. Polyketide β-Branching in Bryostatin Biosynthesis: Identification of Surrogate Acetyl-ACP Donors for BryR, an HMG-ACP Synthase
23. Structural Basis for Binding Specificity between Subclasses of Modular Polyketide Synthase Docking Domains
24. In Vivo and In Vitro Trans-Acylation by BryP, the Putative Bryostatin Pathway Acyltransferase Derived from an Uncultured Marine Symbiont
25. Polyketide Biosynthesis: Modular Polyketide Synthases
26. Interrogating the Molecular Basis for Multiple Macrolactone Ring Formation by the Pikromycin Polyketide Synthase
27. Antitumor Activity of PR-171, a Novel Irreversible Inhibitor of the Proteasome
28. Substrate Profile Analysis and ACP‐Mediated Acyl Transfer in Streptomyces coelicolor Type III Polyketide Synthases
29. Correction: Graduate Education in Chemical Biology at the University of Michigan
30. Pharmacokinetics, Pharmacodynamics and Anti-Tumor Efficacy of PR-171, a Novel Inhibitor of the 20S Proteasome.
31. Biochemical and Cellular Characterization of the Novel Proteasome Inhibitor PR-171.
32. A Proteasome Specific Binding Assay for Quantitation of Constitutive and Immunoproteasome Active Sites.
33. Parallel Synthesis of Glycomimetic Libraries: Targeting a C-Type Lectin
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.